Blood Disorder Therapeutics Market

Executive Summary

Blood Disorder Therapeutics Market was valued at US $60.39 billion in 2021 and is projected to grow at 13.03% CAGR over the forecast period to reach US $125.91 billion by 2027. Blood Disorder Therapeutics Market represented US $13.12 billion opportunity over 2019-2021 and estimated to create US $65.52 billion opportunity in 2027 over 2021.

Blood Disorder Therapeutics from Consainsights analyses the Blood Disorder Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Blood Disorder Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Blood Disorder Therapeutics segmentation includes Product Type, Application and Geography.

Based on the Product Type, the Blood Disorder Therapeutics analysis covers Plasma Derived Factors, Recombinant Factors, Other Products.

In Product Type segment, Plasma Derived Factors segment has highest cagr growth of 11.50%.

Based on the Application, the Blood Disorder Therapeutics analysis covers Hemoglobin Diosrders, Platelet Based Disorders, Plasma Disorders, Myeloproliferative Disorders, Genetic Hematology Disorders, Blood Cancers, Other Application.

In Application segment, Hemoglobin Diosrders segment has highest cagr growth of 11.50%.

Based on the region, the Blood Disorder Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc, Amgen Inc, AstraZeneca Plc and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, Plasma Derived Factors segment has the highest revenue of US $32.94 billion and is expected to grow at CAGR of 11.50% by 2027 Plasma Derived Factors segment has highest cagr growth of 11.50%.

Plasma Derived Factors

Plasma Derived Factors segment was valued at US $25.78 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $68.68 billion by 2027. Plasma Derived Factors segment represented US $7.16 billion opportunity over 2019-2021 and estimated to create US $35.74 billion opportunity in 2027 over 2021.

Recombinant Factors

Recombinant Factors segment was valued at US $19.71 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $52.49 billion by 2027. Recombinant Factors segment represented US $5.47 billion opportunity over 2019-2021 and estimated to create US $27.31 billion opportunity in 2027 over 2021.

Other Products

Other Products segment was valued at US $1.78 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $4.75 billion by 2027. Other Products segment represented US $0.49 billion opportunity over 2019-2021 and estimated to create US $2.47 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Hemoglobin Diosrders segment has the highest revenue of US $23.81 billion and is expected to grow at CAGR of 11.50% by 2027 Hemoglobin Diosrders segment has highest cagr growth of 11.50%.

Hemoglobin Diosrders

Hemoglobin Diosrders segment was valued at US $18.64 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $49.65 billion by 2027. Hemoglobin Diosrders segment represented US $5.17 billion opportunity over 2019-2021 and estimated to create US $25.83 billion opportunity in 2027 over 2021.

Platelet Based Disorders

Platelet Based Disorders segment was valued at US $12.04 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $32.06 billion by 2027. Platelet Based Disorders segment represented US $3.34 billion opportunity over 2019-2021 and estimated to create US $16.68 billion opportunity in 2027 over 2021.

Plasma Disorders

Plasma Disorders segment was valued at US $6.25 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $16.64 billion by 2027. Plasma Disorders segment represented US $1.73 billion opportunity over 2019-2021 and estimated to create US $8.66 billion opportunity in 2027 over 2021.

Myeloproliferative Disorders

Myeloproliferative Disorders segment was valued at US $4.85 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $12.92 billion by 2027. Myeloproliferative Disorders segment represented US $1.35 billion opportunity over 2019-2021 and estimated to create US $6.72 billion opportunity in 2027 over 2021.

Genetic Hematology Disorders

Genetic Hematology Disorders segment was valued at US $2.89 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $7.70 billion by 2027. Genetic Hematology Disorders segment represented US $0.80 billion opportunity over 2019-2021 and estimated to create US $4.01 billion opportunity in 2027 over 2021.

Blood Cancers

Blood Cancers segment was valued at US $2.01 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $5.35 billion by 2027. Blood Cancers segment represented US $0.56 billion opportunity over 2019-2021 and estimated to create US $2.78 billion opportunity in 2027 over 2021.

Other Application

Other Application segment was valued at US $0.60 billion in 2019 and is projected to grow at 11.50% CAGR over the forecast period to reach US $1.60 billion by 2027. Other Application segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.83 billion opportunity in 2027 over 2021.